Skip to main content

Multiple sclerosis

Multiple sclerosis

17-01-2019 | Multiple sclerosis | News | Article

Early aggressive treatment to delay conversion to secondary progressive MS

The findings from two studies published in JAMA show the benefits of initial disease-modifying therapy and nonmyeloablative haematopoietic stem cell transplantation in delaying conversion to secondary progressive multiple sclerosis.

10-01-2019 | Multiple sclerosis | News | Article

Rituximab shows disability benefits in patients with secondary progressive MS

Rituximab treatment may reduce and delay disability progression in patients with secondary progressive multiple sclerosis, show findings from a comprehensive real-world cohort study.

25-10-2018 | Multiple sclerosis | News | Article

Medicinal cannabinoids show small antispastic and analgesic benefits for MS patients

The benefits of medicinal cannabinoids for the treatment of spasticity, pain and bladder dysfunction in patients with multiple sclerosis may be limited, suggests a systematic review and meta-analysis.

13-09-2018 | Multiple sclerosis | News | Article

Fingolimod shows relapse benefits versus interferon beta-1a in paediatric multiple sclerosis

Adolescents with multiple sclerosis may experience fewer relapses if they take fingolimod versus interferon beta-1a, suggest findings from the phase III PARADIGMS trial.

MRI brain scan

30-08-2018 | Multiple sclerosis | News | Article

Ibudilast slows brain shrinkage in progressive multiple sclerosis patients

Ibudilast may slow brain atrophy in patients with progressive multiple sclerosis, show findings from a phase II study.

23-08-2018 | Neurology | News | Article

Novel MS subtype suggests neurodegeneration and demyelination occur independently

Researchers have discovered a new subtype of multiple sclerosis that features neuronal loss but not demyelination of the brain’s white matter.

09-08-2018 | Multiple sclerosis | News | Article

Lower risk of disability progression in primary progressive versus progressive-relapsing MS

Superimposed relapses are associated with a lower risk of confirmed disability progression among individuals with progressive-onset multiple sclerosis, suggest the results of an observational cohort study published in JAMA Neurology.

14-02-2017 | Multiple sclerosis | News | Article

Alemtuzumab compares favorably with other potent immunotherapies for MS

Researchers suggest that alemtuzumab is comparable to natalizumab for controlling multiple sclerosis activity and superior to fingolimod and interferon beta.

07-02-2017 | Multiple sclerosis | News | Article

Immunosuppression and stem cell transplants achieve sustained MS remission

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation can induce long-term remission for patients with relapsing–remitting multiple sclerosis, show findings from the HALT-MS trial.

26-01-2017 | Multiple sclerosis | News | Article

Serious adverse effect with alemtuzumab reported

Researchers have highlighted the occurrence of severely exacerbated central nervous system inflammation in two patients taking alemtuzumab for multiple sclerosis.

Brain nerve cell

04-01-2017 | Multiple sclerosis | News | Article

Ocrelizumab shows promise in primary progressive and relapsing–remitting MS

Phase 3 trial results have shown the benefits of ocrelizumab for reducing disability progression in patients with primary progressive multiple sclerosis and disease activity in patients with the relapsing–remitting disease subtype.

08-12-2016 | Multiple sclerosis | News | Article

Newborn vitamin D status linked to future MS risk

Babies born with low levels of vitamin D may be at increased risk for multiple sclerosis in later life, suggests research.

IV drip 2

19-10-2016 | Multiple sclerosis | News | Article

MS drug may reduce not just slow disability symptoms

Alemtuzumab improves pre-existing disability in multiple sclerosis patients rather than just slowing its progression, shows analysis of the CARE-MS II trial.

03-10-2016 | Multiple sclerosis | News | Article

Physical activity fails to halt MS risk

Exercise does not reduce women’s risk of developing multiple sclerosis, an analysis of data on more than 193,000 women shows.

23-08-2016 | Multiple sclerosis | News | Article

Amiselimod gains MOMENTUM in the treatment of multiple sclerosis

Amiselimod shows potential for the treatment of relapsing–remitting multiple sclerosis, without the cardiac side effects associated with other sphingosine 1-phosphate 1 receptor modulators, phase II study findings show.

15-08-2016 | Multiple sclerosis | News | Article

Long-term BENEFIT of early MS treatment confirmed

The 11-year follow-up results of the BENEFIT trial emphasize the importance of initiating treatment early in individuals exhibiting the signs of multiple sclerosis onset, say researchers who observed long-lasting improvements in disease progression and disability.

MRI scanner

18-07-2016 | Multiple sclerosis | News | Article

Revised MRI criteria improve MS diagnosis accuracy

Researchers believe that, when diagnosing multiple sclerosis, lesions in the symptomatic region should not be excluded, as stated in the McDonald dissemination in space criteria.

Clear vial_injection 2

21-06-2016 | Multiple sclerosis | News | Article

Switch to rituximab shows anti-inflammatory effect in relapsing–remitting MS

Rituximab may be an attractive treatment option for patients with relapsing–remitting multiple sclerosis, suggest phase II study findings showing its efficacy in controlling inflammatory activity.

Stem cells

10-06-2016 | Multiple sclerosis | News | Article

Immunoablation strengthens haemopoietic stem-cell transplantation effects in MS

Intensifying current transplant conditioning to remove rather than suppress immune cells ahead of autologous haematopoietic stem cell transplantation may result in long-term remission of multiple sclerosis, phase II trial findings show.

02-06-2016 | Multiple sclerosis | News | Article

HLA genetic risk burden extends to MS outcomes

Human leukocyte antigen alleles not only increase susceptibility to multiple sclerosis, but also influence the course of the disease, suggests research.